Miami, FL – August 2024 – Cellgenic, a division of Global Stem Cells Group and a global leader in regenerative medicine, is pleased to announce its sponsorship of three major medical events in Peru this September, where the company will prominently feature its advanced exosome and peptide products. This sponsorship underscores Cellgenic’s commitment to expanding its presence in the rapidly growing Latin American market for regenerative medicine.

Event Details:

• International Regenerative Medicine Conference by ISSCA – September 6-7, 2024: Taking place at the prestigious Hilton Hotel, this event, hosted by the International Society for Stem Cell Application (ISSCA), will gather leading experts from around the world to discuss the latest advancements in stem cell research and regenerative therapies.
• AMDAL 2024 – September 14-15, 2024: Held at the Sol de Oro Hotel in Miraflores, AMDAL 2024 will focus on the latest innovations in dermatology and laser treatments. This event will bring together professionals from across the medical and aesthetic fields to explore cutting-edge technologies and practices.
• MDE24 International Congress of Medicine and Aesthetic Dermatology – September 20-21, 2024: This event, set to take place at the ESAN Convention Center, will highlight groundbreaking developments in aesthetic dermatology and medical treatments, attracting participants from across the globe.

These events will feature a diverse lineup of international and local speakers, as well as participating doctors from Peru and neighboring regions. As a sponsor, Cellgenic will have a unique opportunity to introduce its pioneering exosome technology to the attending medical professionals, demonstrating why exosomes represent a promising and expanding market in Latin America.

“Cellgenic is honored to participate in these prestigious events, where we will showcase our latest innovations in regenerative medicine,” said Benito Novas, Founder of Global Stem Cells Group. “We are particularly excited to introduce our exosome products to a new audience in this region. Additionally, we are leveraging these platforms to officially launch our new line of peptides, which we believe could offer significant benefits to medical professionals and patients alike.”

Exosomes, derived from mesenchymal stem cells, have been increasingly recognized for their potential in enhancing regenerative processes, offering new avenues for treatment in areas such as aesthetic medicine, orthopedics, and chronic conditions. The Latin American market, with its growing focus on advanced medical therapies, might be poised for significant growth in the adoption of exosome-based treatments.

Sarah Barroso, Director of Cellgenic, emphasized the strategic importance for the company’s presence in Peru. “Doctors in Peru have consistently shown a strong interest in our exosome products, and our participation in these conferences represents a crucial opportunity for us to expand our footprint in this promising market,” Barroso stated. “We are confident that our exosomes and peptides will meet the evolving needs of healthcare professionals in the region, providing them with innovative tools to improve patient outcomes.”

About Cellgenic

As a division of Global Stem Cells Group, Cellgenic is driven by a commitment to lead the way in regenerative medicine. By continuously expanding its product offerings, including exosomes and peptides, and staying at the forefront of scientific research, Cellgenic aims to meet the increasing demand for advanced, effective, and safe therapies in Latin America and beyond. The potential of exosomes and peptides to revolutionize patient care might position Cellgenic as a key player in this rapidly evolving landscape.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, FL — Global Stem Cells Group (GSCG), a renowned leader in regenerative medicine, proudly announces the launch of its innovative Cellgenic peptide line. Cellgenic, the division of GSCG that promotes and distributes innovative products and equipment for physicians in the field of regenerative medicine, introduces this new line of peptides, once again solidifying its mission to provide physicians with cutting-edge solutions to improve patient care.

Peptides in the Field of Regenerative Medicine

Peptides play a crucial role in the field of regenerative medicine by promoting healing, reducing inflammation, and enhancing cellular function. They serve as signaling molecules that can influence various biological processes, making them an alternative in the treatment of injuries, chronic conditions, and age-related degeneration. By integrating peptides into their product offerings, Cellgenic intends to provide healthcare professionals with powerful tools to improve patient outcomes and advance the efficacy of regenerative therapies. These peptides, when used in conjunction with other cellular therapies, may significantly enhance the body’s natural ability to repair and regenerate tissue.

Cellgenic new peptide line includes:

Healing and Recovery:

1. BPC157: Known for its potential healing properties, BPC157 may accelerate recovery from injuries and support overall tissue repair. This peptide is derived from a protein found in the stomach and has shown promising effects on the healing of muscles, tendons, and ligaments.
2. TB500: A potent peptide that may enhance muscle recovery and reduce inflammation, TB500 is ideal for athletes and individuals with chronic injuries. It mimics the effects of Thymosin Beta-4, a naturally occurring peptide that plays a crucial role in the body’s healing process by potentially promoting cellular migration and differentiation.

Anti-Aging and Skin Health:

3. GHK-CU: Widely recognized for its potential anti-aging effects, GHK-CU may improve skin appearance and promote wound healing. This copper peptide can stimulate collagen production, enhance skin elasticity, and has shown promise in reducing fine lines and wrinkles, making it a popular choice in cosmetic treatments.
4. Epithalon: Known for its potential ability to regulate the pineal gland, Epithalon may enhance longevity and overall health. It has been studied for its potential to lengthen telomeres, which are protective caps on chromosomes that shorten with age, thereby promoting cellular health and longevity.

Metabolic and Longevity:

5. MOTS-C: This mitochondrial-derived peptide plays a critical role in regulating metabolic functions and promoting longevity. MOTS-C can enhance the body’s ability to convert glucose into energy, which may improve physical performance, increase muscle strength, and support overall metabolic health.
6. SS31: A unique peptide that targets and protects mitochondria, SS31 is instrumental in reducing oxidative stress and improving cellular function. This peptide has shown promise in treating conditions related to mitochondrial dysfunction, such as neurodegenerative diseases and muscle wasting.

Aesthetic and Sexual Health:

7. Melanotan 2: This peptide is widely used for its potential to enhance tanning and improve sexual function. Melanotan 2 stimulates the production of melanin, the pigment responsible for skin color, providing a sunless tanning option and also has aphrodisiac effects.

Growth Hormone and Body Composition:

8. Ipamorelin: As a growth hormone secretagogue, Ipamorelin may be effective for improving body composition and supporting muscle growth. It stimulates the release of growth hormone without affecting cortisol levels, making it a potentially safe and effective option for increasing lean body mass and reducing body fat.
9. Tesamorelin: Known for its ability to increase growth hormone levels, Tesamorelin can be beneficial for improving body composition and metabolic health. It is particularly effective in reducing visceral fat in patients with HIV-associated lipodystrophy and has potential benefits for general weight management.

Weight Management and Diabetes:

10. Semaglutide: A GLP-1 agonist, Semaglutide can be effective for weight loss and managing diabetes. It works by mimicking the hormone GLP-1, which increases insulin secretion, reduces appetite, and slows gastric emptying, thereby promoting weight loss and improving blood sugar control.
11. Tirzepatide: Another GLP-1 agonist, Tirzepatide, is gaining recognition for its significant impact on weight loss and metabolic regulation. It combines the actions of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), providing enhanced effects on blood sugar control and weight reduction.

Global Stem Cells Group Remains a Leader in the Industry

Global Stem Cells Group’s commitment to innovation and excellence sets it apart from the competition. By continually thinking in ways that others do not, GSCG remains a pioneering force in regenerative medicine. Its approach involves not only developing cutting-edge products but also fostering a collaborative environment with researchers, healthcare providers, and industry experts to ensure the highest standards of quality and efficacy. GSCG’s comprehensive education and training programs further underscore their dedication to advancing the field, ensuring that medical professionals worldwide are well-equipped to utilize the latest regenerative therapies.

Expanding Horizons with Innovative Solutions

Global Stem Cells Group’s growth trajectory is remarkable. With multiple offices around the globe and plans for further expansion, GSCG is dedicated to increasing its outreach and impact in the field of regenerative and restorative medicine. This expansion is not just about opening new offices but also about forging partnerships and collaborations that enhance the company’s ability to deliver state-of-the-art treatments and products. The launch of this new line of peptides is a testament to its unwavering commitment to innovation and excellence, strengthening GSCG’s position as a global leader in regenerative medicine for now and long into the future.

About Cellgenic

Cellgenic is a distinguished brand renowned for its cellular products and kits featuring the latest advancements in regenerative medicine, including Exosomes, Collagenase, PRP, Wharton’s jelly mesenchymal cells, and now peptides. Committed to excellence in research and development, Cellgenic strives to provide healthcare professionals with cutting-edge technologies of the highest quality to enhance patient care and outcomes.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida –  Global Stem Cells Group (GSCG) is delighted to announce the grand opening of ReGen Mediterra, a state-of-the-art facility located in the picturesque city of Antalya, Turkey. This new addition to the ReGen Network marks a significant advancement in the field of regenerative medicine and underscores GSCG’s dedication to providing innovative healthcare solutions on a global scale.

Expanding Medical Tourism in Antalya

Antalya, renowned for its breathtaking beaches and stunning landscapes, is one of Turkey’s most sought-after tourist destinations. The city’s allure as a premier hub for medical tourism is further amplified by the establishment of ReGen Mediterra. The facility is poised to attract patients not only from Turkey but from across Europe, seeking cutting-edge anti-aging treatments, advanced stem cell therapies, and non-invasive methods to address various health conditions.

Commitment to Excellence in Regenerative Medicine

“The expansion of the ReGen Clinic network solidifies our position as the largest regenerative medicine network globally. Antalya’s unique position as a top tourist destination makes it an ideal location for medical tourism, offering patients the opportunity to receive world-class treatments while enjoying the region’s natural beauty,” stated Dr. Salih Yildirim, Director of ReGen and President of the International Society for Stem Cell Application (ISSCA).

Stem cell therapy is emerging as an increasingly effective clinical solution for treating conditions that traditional medicine addresses primarily through palliative care and pain management. Patients worldwide are seeking natural regenerative alternatives that offer a reduced risk of potential side effects associated with conventional pharmaceuticals.

Advancing Accessibility and Training

The opening of ReGen Mediterra will facilitate the transition of stem cell therapy and regenerative medicine from elective procedures to accessible treatments for patients throughout Turkey. In addition to providing advanced treatments, the center will serve as a training hub for the International Society for Stem Cell Application (ISSCA), thereby enhancing the knowledge and expertise of healthcare professionals in the region.

Inauguration Ceremony and Conference Highlights

The inauguration ceremony was complemented by a conference, offering regional physicians an opportunity to gain insights into the latest technologies in regenerative medicine and cell therapy. This event underscores GSCG’s commitment to fostering education and collaboration within the medical community.

Future Prospects

As ReGen Mediterra begins its operations, it aims to set new benchmarks in the field of regenerative medicine. The facility will focus on delivering patient-centric care, leveraging the latest advancements in medical technology, and maintaining the highest standards of clinical practice. By doing so, GSCG hopes to make significant contributions to the well-being of patients and the advancement of medical tourism in Antalya.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

About ReGen

ReGen is a highly acclaimed Turkish company with clinics in Turkey and several other locations around the world, renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – Global Stem Cells Group (GSCG) is thrilled to announce the grand opening of its latest state-of-the-art Stem Cell Center, located in Jakarta, Indonesia. This new facility, under the membership of ReGen Network, marks the second center in Jakarta and the fourth in Indonesia, reflecting GSCG’s rapid and explosive growth within the regenerative medicine industry.

“Witnessing the rapid and dynamic growth of the regenerative medicine industry, particularly through the pioneering efforts of experts like Dr. Yanti, our medical director in Indonesia, is truly inspiring,” said Benito Novas, a prominent figure in regenerative medicine and the head of Public Relations for GSCG and the International Society for Stem Cell Application (ISSCA).

“The expansion of the ReGen Clinic network solidifies our position as the largest regenerative medicine network globally. Our mission is to implement the best practices in regenerative medicine across various regions, ensuring effective and transformative results,” stated Dr. Salih Yildirim, Director of ReGen and President of ISSCA.

This momentous occasion marks a significant stride forward in the field of regenerative medicine and showcases GSCG’s commitment to providing innovative healthcare solutions worldwide. In a groundbreaking partnership with an esteemed local aesthetic clinic, GSCG introduces its fourth Stem Cell Center in Indonesia, complementing existing facilities in Jakarta, Surabaya, and Bandung. Further underscoring their dedication to advancing medical research, GSCG also anticipates the unveiling of a fifth facility in Bali this year.

ReGen is at the forefront of introducing cutting-edge aesthetic and regenerative treatments, revolutionizing the healthcare landscape. Patients now can have access to the latest treatment options. This partnership underscores Global Stem Cells Group’s vision to make its exceptional services accessible to people around the world.

“We are very proud to be part of ReGen and to contribute to the advancement of regenerative medicine in Indonesia. This new center in Jakarta represents our commitment to providing top-tier medical care and innovative treatments to our patients,” said Dr. Yanti Khusmiran, Medical Director of ReGen Facilities in Indonesia.

While ReGen brings access to clinics, advanced techniques, and expertise, Global Stem Cells Group provides valuable resources as a conglomerate of companies engaged in product manufacturing and comprehensive training through ISSCA. This collaboration has the potential to change the lives of people seeking regenerative care on a global scale.

The newly established center will also serve as a training hub for ISSCA, contributing to the enhancement of knowledge and expertise among healthcare professionals in the region. The opening ceremony was accompanied by onsite training conducted by ISSCA, explaining to all staff standards of practice in regenerative medicine, medical applications of stem cells, and exosomes.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

About ReGen

ReGen is a highly acclaimed Turkish company with clinics in Turkey and several other locations around the world, renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.

About Dr. Yanti Aesthetic Clinic

 Dr. Yanti Aesthetic Clinic is a revered healthcare institution renowned for its state-of-the-art aesthetic and regenerative treatments. With an unwavering dedication to excellence and a forward-thinking approach, Dr. Yanti Aesthetic Clinic is poised to shape the future of regenerative medicine in Indonesia and beyond.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida– The International Society for Stem Cell Application (ISSCA), a distinguished division of the Global Stem Cells Group (GSCG), is thrilled to announce a series of upcoming events in 2024 dedicated to advancing the field of regenerative medicine.

With over 15 years of leadership in regenerative medicine, ISSCA has been a pioneer in non-profit education, dedicated to allowing physicians to present the benefits of stem cell medicine to patients worldwide and establishing itself as a global leader in certification, education, research, and training in regenerative medicine.

Mastering the Next Generation of Regenerative Medicine and Cellular Therapy

The “Leading the Charge: Mastering Next-Generation Cellular Therapies” course is scheduled for October 4-5. This course is designed to provide participants with a deep understanding of the most advanced cellular therapies. The course focuses on natural killer cells (NK), cutting-edge Cellgenic cellular products, and therapeutic peptides, along with practical techniques for effective application of these therapies. This innovative course updates the latest accessible technologies for doctors and includes protocols for biohacking at the cellular level, state-of-the-art technologies, and therapeutic applications.

International Conference in Peru

On September 6-7, ISSCA will host a prestigious conference in Lima, Peru, expected to draw hundreds of physicians. This event will provide a unique platform to discuss the latest advancements in regenerative medicine and stem cell therapy. Attendees will have the opportunity to engage in presentations and workshops led by top doctors and scientists from around the world, sharing extensive knowledge and insights. The conference will also offer invaluable networking opportunities with newly established clinics, fostering collaboration and advancing medical knowledge within the region.

International Conference in Argentina

Following the Peru event, ISSCA will hold another significant conference in Buenos Aires, Argentina on October 25-26. This conference aims to continue the momentum by bringing together hundreds of physicians to discuss the most recent developments in regenerative medicine. This gathering underscores the Global Stem Cells Group’s commitment to promoting collaboration and knowledge exchange in the field of regenerative medicine in Argentina and South America.

International Conference in Dubai

The series of international conferences will culminate with an event in Dubai, UEA on November 30 – December 1. This conference is expected to attract a large number of physicians from GCC countries. It will provide an exceptional opportunity to explore the latest advancements in regenerative medicine and stem cell therapy. The event will also facilitate valuable networking opportunities, helping to establish connections and collaborations in the rapidly evolving field of regenerative medicine.

These conferences will feature a full schedule of lectures highlighting significant subjects such as molecular biology, innovative treatment approaches in surgical and cosmetic domains, and the latest cutting-edge technologies in the field. Additionally, the conferences will explore the legal framework encompassing regenerative medicine practices globally, acknowledging the varying degrees of involvement by national governments.

These events are ISSCA’s dedication to facilitating a transformative change from traditional healthcare methods to regenerative medicine. They will showcase the latest innovative discoveries and progress in all aspects of stem cell research.

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.

ISSCA’s mission is to promote the benefits of stem cell medicine to patients globally, ensure the quality and uniformity of regenerative medicine practices, and establish itself as a global leader in the certification and education of medical professionals in this field. The organization is a distinguished division of the Global Stem Cells Group (GSCG) and has over 15 years of experience in the industry, making significant contributions to the advancement and dissemination of regenerative medicine knowledge and practices.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.